Clinical data
Trade names Revanex[1]
ATC code None
Synonyms YH1885
CAS Number 199463-33-7
PubChem (CID) 204104
ChemSpider 176801
Chemical and physical data
Formula C22H23FN4
Molar mass 362.44 g/mol
3D model (Jmol) Interactive image

Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis.[2] It acts as an acid pump antagonist[3] (potassium-competitive acid blocker). Revaprazan is approved for use in Korea,[4] but is not approved in Europe or the United States.


  1. "Revaprazan".
  2. Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS (Oct 2010). "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". J Gastroenterol Hepatol. 25 (10): 1618–1625. doi:10.1111/j.1440-1746.2010.06408.x. PMID 20880169.
  3. Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS (Jan 2004). "Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers". J Clin Pharmacol. 44 (1): 73–82. doi:10.1177/0091270003261321. PMID 14681344.
  4. "Revaprazan Yuhan registered, South Korea (gastritis)". R & D Focus Drug News. September 25, 2006.

This article is issued from Wikipedia - version of the 7/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.